Analysts mean rating score stands at 1.70 while Rexahn Pharmaceuticals, Inc.’s (RNN) stock price is Worth at $0.43: Investors Alert

Rexahn Pharmaceuticals, Inc. (RNN)’s Stock Price Trading Update:

Rexahn Pharmaceuticals, Inc. (RNN) stock price ended its day with loss -2.67% and finalized at the value of $0.43. During its last trading session, Stock traded with the total exchanged volume of 2.44 million shares. The average volume stands around 6.61 million shares. The average numbers of shares are traded in a security per day, during the recent 3-month period. The stock has relative volume of 0.37. Relative volume is ratio between current volume and 3-month average value, intraday adjusted. Rexahn Pharmaceuticals, Inc. (RNN) is a part of Healthcare sector and belongs to Biotechnology industry.

Important Technical Indicators:

ATR value of company was 0.05. Average True Range (ATR) is an indicator based on trading ranges smoothed by an N-period exponential moving average percentage of the true range values. ATR can display volatility of stocks, ETFs and indexes. The principal of ATR is very similar to other volatility indicators: A high ATR value signals a possible trend change. A low ATR value correlates with a weaker trend movement.

Relative Strength Index (RSI) was 46.57. Developed J. Welles Wilder, the Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. Traditionally, and according to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

The stock volatility for week was 8.35% while for month was 11.98%.The stock, as of last close, traded 238.82% to its 52 week low and was changed -39.39% from its 52 week high. Beta factor, which measures the riskiness of the security, was observed as -0.38. RNN’s value Change from Open was at 0.07% with a Gap of -2.74%.

Earnings per share Details about RNN:

EPS growth in past 5 year was 18.90%.

EPS growth in next year is estimated to reach -12.50% while EPS growth estimate for this year is set at 45.70%.

Performance Review:

To review the RNN previous performance, look at its past history, which highlighted below:

During last 5 trades the stock sticks almost 2.45%.

During last one month it showed the change of -10.35%.

During last 3 month it remained at 140.66%.

During last one year month it performed at 41.78%.

Along with these its year to date performance is standing at 203.24%.

Analysts Mean Rating:

Analysts’ mean recommendation for Rexahn Pharmaceuticals, Inc. (RNN) stands at 1.70. Rating Scale; where 1.0 rating means Strong Buy, 2.0 rating signify Buy, 3.0 recommendation reveals Hold, 4.0 rating score shows Sell and 5.0 displays Strong Sell signal.

RNN Stock Price Comparison to Moving Averages:

USA based company, Rexahn Pharmaceuticals, Inc. (RNN)’s latest closing price was 68.62% from the average-price of 200 days while it maintained a distance from the 50 Day Moving Average at 3.83% and -16.57% compared with the 20 Day Moving Average.

Current Analysts Rating Alert about Rexahn Pharmaceuticals, Inc. (RNN) :

Analysts Rating Review: Analysts play a useful role in our capital markets. For example, by doing in-depth research for their large institutional clients and employers, analysts can help substantial sums of capital be directed to more productive uses in our economy. A “Buy” rating does not mean that every investor should acquire the stock. Nor does a “Sell” rating mean that every investor should immediately sell it. Your own financial situation and investment needs are what matter. If you consider any individual rating, do not views it in absolute or abstract terms, but in the context of your own unique financial situation. In short, whatever a given analyst recommendation may say, always consider whether a particular investment is right for you in light of your own financial circumstances. Remember, you are the boss, it’s your money, and your situation and goals that matter. Presently Rexahn Pharmaceuticals, Inc. (RNN) received consensus rating of “ Buy ” from analysts, according to FactSet data. “0” suggested “Sell” for the company. The stock has been rated as “Buy” from “2″ Analysts”. “0” told the company as a “Hold”. Overweight rating was given by “1” and Underweight rating was given by “0”. Analysts’ recommendations are the fountainhead of equity research reports and should be used in tangent with proprietary research and investment methodologies in order to make investment decisions. Additionally, “buy, hold and sell” recommendation meanings are not as transparent as they first seem; a plethora of terms and variance in meanings exist behind the curtain and serve to muddy the waters. It is thus important to understand a firm’s entire scale when assimilating ratings.

 

Leave a Reply

Your email address will not be published. Required fields are marked *